Literature DB >> 1290488

Thrombin-specific inhibition by and slow cleavage of hirulog-1.

J I Witting1, P Bourdon, D V Brezniak, J M Maraganore, J W Fenton.   

Abstract

Hirulog-1 [D-Phe-Pro-Arg-Pro-[Gly]4-desulphohirudin-(53-64) (HV1)] was designed to bind by its first four and last 12 residues to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition respectively, with a [Gly]4 bridge and an Arg-Pro bond at the scissional position. Human alpha-, gamma- and zeta-thrombins, as well as bovine trypsin, readily hydrolyse Spectrozyme-TH (D-hexahydrotyrosyl-Ala-Arg p-nitroanilide) at pH 7.4 and approx. 23 degrees C. Both alpha- and zeta-thrombins, which have high fibrinogen-clotting activities (greater than 3000 kunits/g), were inhibited with this substrate by hirulog-1 [Ki = 2.56 +/- 0.35 nM (n = 3) and 1.84 +/- 0.15 nM (n = 3) respectively] and slowly cleaved the inhibitor [k = 0.326 +/- 0.082 min-1 (n = 12) and 0.362 +/- 0.056 min-1 (n = 18) respectively], whereas gamma-thrombin, which has essentially no clotting activity (approx. 4 kunits/g), and trypsin were not inhibited with greater than 1000-fold molar excess of hirulog-1. Similar inhibition parameters were also obtained for hirulog-1 incubated with alpha-thrombin or zeta-thrombin at approx. 23 degrees C and by measuring thrombin activity with fibrinogen in the clotting assay at 37 degrees C. Cleavage of the Arg-3-Pro-4 bond in hirulog-1 by either alpha- or zeta-thrombin was shown by identical cleavage products of either thrombin on h.p.l.c. and by sequence analysis of the alpha-thrombin products. These data demonstrate that hirulog-1 is a specific inhibitor of thrombin forms with high fibrinogen-procoagulant activities and that its Arg-3-Pro-4 bond is slowly cleaved by these thrombin forms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290488      PMCID: PMC1130947          DOI: 10.1042/bj2830737

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  52 in total

Review 1.  Regulation of thrombin generation and functions.

Authors:  J W Fenton
Journal:  Semin Thromb Hemost       Date:  1988-07       Impact factor: 4.180

2.  Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N alpha-acetyl-hirudin45-65.

Authors:  J L Krstenansky; S J Mao
Journal:  FEBS Lett       Date:  1987-01-19       Impact factor: 4.124

3.  Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity.

Authors:  S J Mao; M T Yates; T J Owen; J L Krstenansky
Journal:  Biochemistry       Date:  1988-10-18       Impact factor: 3.162

4.  A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors.

Authors:  P J Henderson
Journal:  Biochem J       Date:  1972-04       Impact factor: 3.857

Review 5.  Thrombin specificity.

Authors:  J W Fenton
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

Review 6.  Thrombin active-site regions.

Authors:  J W Fenton; D H Bing
Journal:  Semin Thromb Hemost       Date:  1986-07       Impact factor: 4.180

7.  Human alpha- and gamma-thrombin specificity with tripeptide p-nitroanalide substrates under physiologically relevant conditions.

Authors:  J I Witting; T M Miller; J W Fenton
Journal:  Thromb Res       Date:  1987-05-15       Impact factor: 3.944

8.  Thrombin inhibition with dipeptidyl argininals.

Authors:  J I Witting; C Pouliott; J L Catalfamo; J Fareed; J W Fenton
Journal:  Thromb Res       Date:  1988-05-15       Impact factor: 3.944

9.  Identification of regions of alpha-thrombin involved in its interaction with hirudin.

Authors:  S R Stone; P J Braun; J Hofsteenge
Journal:  Biochemistry       Date:  1987-07-28       Impact factor: 3.162

10.  Catalytic competence of human alpha- and gamma-thrombin in the activation of fibrinogen and factor XIII.

Authors:  S D Lewis; L Lorand; J W Fenton; J A Shafer
Journal:  Biochemistry       Date:  1987-12-01       Impact factor: 3.162

View more
  13 in total

1.  Hirulog-1 and -B2 thrombin specificity.

Authors:  J I Witting; P Bourdon; J M Maraganore; J W Fenton
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

Review 2.  Direct thrombin inhibitors in cardiovascular disease.

Authors:  Kyle A Arsenault; Jack Hirsh; Richard P Whitlock; John W Eikelboom
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

Review 3.  New anticoagulant drugs.

Authors:  J I Weitz
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

4.  High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: identification of two binding domains.

Authors:  H R Gralnick; S Williams; L P McKeown; K Hansmann; J W Fenton; H Krutzsch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

5.  Bivalirudin as a bridge for anticoagulation in high risk neurosurgical patients with active DVT or high risk of thrombosis.

Authors:  Tariq Janjua; Eric Nussbaum; Jodi Lowary; Virginia Babbini
Journal:  Neurocrit Care       Date:  2013-06       Impact factor: 3.210

Review 6.  Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?

Authors:  John W Eikelboom; John French
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors.

Authors:  Cho Yeow Koh; Sundramurthy Kumar; Maria Kazimirova; Patricia A Nuttall; Uvaraj P Radhakrishnan; Seongcheol Kim; Pudur Jagadeeswaran; Takayuki Imamura; Jun Mizuguchi; Sadaaki Iwanaga; Kunchithapadam Swaminathan; R Manjunatha Kini
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

Review 8.  New anticoagulants for the prevention and treatment of venous thromboembolism.

Authors:  Simon J McRae; Jeffrey S Ginsberg
Journal:  Vasc Health Risk Manag       Date:  2005

9.  Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.

Authors:  Asif Iqbal; Mauricio Barbugiani Goldfeder; Rafael Marques-Porto; Huma Asif; Jean Gabriel de Souza; Fernanda Faria; Ana Marisa Chudzinski-Tavassi
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

10.  A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity.

Authors:  Zhuguo Liu; Zheng Yu; Yuanyuan Huang; Yan Zhang; Guozhu Han; Xian Li; Mingxin Dong; Shuo Yu; Yu Wang; Jie Hu; Huiqin Guo; Yuanguo Cheng; Li Lv; Qiuyun Dai
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.